Cargando…

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY

BACKGROUND: Upadacitinib (UPA), an oral selective and reversible JAK inhibitor, demonstrated significantly greater efficacy compared with placebo (PBO) for induction of remission in patients with moderately to severely active ulcerative colitis (UC) in two phase 3 induction trials. AIMS: Evaluate sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panaccione, R, Danese, S, Zhouwen, W, Pangan, A, Hébuterne, X, Nakase, H, D’Haens, G, Panes, J, Lindsay, J, Higgins, P, Loftus, E, Sandborn, W, Xie, W, Sanchez gonzalez, Y, Liu, J, Weinreich, M, Vermeire, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Poster of Distinction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859192/ http://dx.doi.org/10.1093/jcag/gwab049.144

Ejemplares similares

A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY
por: Panaccione, R, et al.
Publicado: (2022)

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data
por: Danese, Silvio, et al.
Publicado: (2023)

Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results
por: Panés, Julian, et al.
Publicado: (2023)

A54 DIETARY COMPONENTS ARE ASSOCIATED WITH FECAL CALPROTECTIN IN ULCERATIVE COLITIS
por: Chiu, E, et al.
Publicado: (2022)

A158 COMPARING CORTIMENT® AND PREDNISONE IN ULCERTATIVE COLITIS: A POPULATION-BASED STUDY OF OUTCOMES
por: Coward, S, et al.
Publicado: (2022)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

A118 UPPER GASTROINTESTINAL HEMORRHAGE SECONDARY TO SUPERIOR MESENTERIC ARTERY PSEUDOANEURYSM: CASE REPORT AND REVIEW OF LITERATURE
por: Guo, H, et al.
Publicado: (2022)

Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis
por: Ghosh, Subrata, et al.
Publicado: (2021)

Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease
por: Sandborn, William J, et al.
Publicado: (2021)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

A156 MUCOSA-ASSOCIATED MICROBIOTA OF ILEOCOLONIC CROHN’S DISEASE PATIENTS IS DISTINCT FROM COLONIC CROHN’S DISEASE AND ULCERATIVE COLITIS PATIENTS INDEPENDENT OF BIOPSY SITE, ENDOSCOPIC INFLAMMATION AND HOST GENETICS
por: Hernandez-Rocha, C, et al.
Publicado: (2022)

A44 PGC1-α INHIBITION WORSENS DSS-INDUCED COLITIS IN MICE
por: Oliveira Ponce, J P, et al.
Publicado: (2022)

A154 COMPARING RESPONSE TO INTRAVENOUS IRON INFUSION IN CROHN’S DISEASE AND ULCERATIVE COLITIS
por: Su, S, et al.
Publicado: (2022)

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS
por: Albino, L, et al.
Publicado: (2022)

Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
por: Ernest-Suarez, Kenneth, et al.
Publicado: (2023)

A35 DNA HYPOMETHYLATION INHIBITS TUFT CELL-DERIVED COLITIS-ASSOCIATED CANCER
por: Larsen, F, et al.
Publicado: (2022)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

A48 LYOPHILIZED FECAL MICROBIOTA TRANSPLANT (FMT) DELAYS THE ONSET OF SPONTANEOUS COLITIS IN MUC2-/- MICE
por: Chan, J J, et al.
Publicado: (2023)

A87 HEALTHCARE PROVIDER SATISFACTION WITH VIRTUAL CARE DELIVERY IN ALBERTA DURING THE COVID-19 PANDEMIC.
por: Olayinka, L, et al.
Publicado: (2021)

A73 CANADIAN INFLAMMATORY BOWEL DISEASE MOBILE APPS: CURRENT LANDSCAPE AND NEEDS
por: Chiew, B A, et al.
Publicado: (2022)

A48 OPTIMIZATION OF TRYPTOPHAN-CONTAINING DIETS TO ACTIVATE THE ARYL HYDROCARBON RECEPTOR AND REDUCE SUSCEPTIBILITY TO COLITIS
por: Rondeau, L, et al.
Publicado: (2022)

A57 ULCERATIVE COLITIS DISEASE ACTIVITY IS DOMINATED BY INNATE IMMUNITY AND FEATURES OF TISSUE REMODELING
por: Madill-Thomsen, K, et al.
Publicado: (2022)

A182 THE LACK OF CHROMOGRANIN A IMPACTS COLONIC EPITHELIAL CELLS MARKERS IN AN EXPERIMENTAL MODEL OF ULCERATIVE COLITIS
por: Tshikudi, D M, et al.
Publicado: (2022)

A157 DEFINITIONS OF MEDITERRANEAN DIET INCONSISTENTLY ASSOCIATE WITH MARKERS OF GUT BARRIER FUNCTION OR SUBCLINICAL INFLAMMATION IN A POPULATION-BASED COHORT
por: Neustaeter, A, et al.
Publicado: (2022)

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme
por: Sandborn, William J, et al.
Publicado: (2022)

A160 MOLECULAR ANALYSIS OF THE INJURY-REPAIR RESPONSE IN ULCERATIVE COLITIS REVEALS HETEROGENEITY IN DISEASE ACTIVIT
por: Madill-Thomsen, K, et al.
Publicado: (2022)

A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES
por: Cooper, J, et al.
Publicado: (2022)

A97 DEVELOPMENT OF PREDICTION MODELS FOR THE TRIAGING OF REFERRALS OF INDIVIDUALS WITH SUSPECTED INFLAMMATORY BOWEL DISEASE TO IMPROVE PROMPT ACCESS TO CARE
por: St-Pierre, J, et al.
Publicado: (2022)

A35 FORECASTING THE INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASE: A CANADIAN NATION-WIDE ANALYSIS
por: Coward, S, et al.
Publicado: (2023)

Ulcerative Colitis: Shifting Sands
por: D’Haens, Geert R. A. M., et al.
Publicado: (2019)

A54 THE IMPACT OF NON-INVASIVE TRANSCUTANEOUS AURICULAR VAGUS NERVE STIMULATION (NITAVNS) ON THE DEVELOPMENT OF EXPERIMENTAL COLITIS IN MICE
por: Hesampour, F, et al.
Publicado: (2023)

Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies
por: Mukherjee, Arnab, et al.
Publicado: (2022)

A49 TWO NOVEL LIVE BIOTHERAPEUTIC PRODUCTS PROTECT DSS-EXPOSED MICE FROM ACUTE COLITIS WHEN COMPARED TO 5-ASA
por: Verdugo Meza, A, et al.
Publicado: (2023)

A51 INTESTINAL MICROBIOTA DETERMINES ARYL HYDROCARBON RECEPTOR ACTIVATION AND SUSCEPTIBILITY TO COLITIS
por: Rondeau, L, et al.
Publicado: (2023)

A236 ASSOCIATION OF STOOL METABOLOMIC PROFILE AND MICROBIOME COMPOSITION RISK SCORE WITH FUTURE ONSET OF CROHN’S DISEASE
por: Lee, S, et al.
Publicado: (2022)

A173 INNOVATIVE CARE FOR INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC: USE OF BEDSIDE INTESTINAL ULTRASOUND TO OPTIMIZE MANAGEMENT
por: Novak, K L, et al.
Publicado: (2021)

A101 BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM OCCURRING POST-LIVER TRANSPLANT FOR PSC WITH CLINICAL REMISSION OF ULCERATIVE COLITIS AFTER STEM CELL TRANSPLANTATION
por: Donaldson, M A, et al.
Publicado: (2022)

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial
por: Vermeire, Séverine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nbstn8vl802148raithdhge2mm